Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Matthew Dun"'
Autor:
Abed Rahman Kawakibi, Rohinton Tarapore, Sharon Gardner, Andrew Chi, Sylvia Kurz, Patrick Y Wen, Isabel Arrillaga-Romany, Tracy Batchelor, Nicholas Butowski, Ashley Sumrall, Nicole Shonka, Rebecca Harrison, John DeGroot, Minesh Mehta, Yazmin Odia, Matthew Hall, Doured Daghistani, Timothy Cloughesy, Benjamin Ellingson, Michelle Kim, Yoshie Umemura, Hugh Garton, Andrea Franson, Jonathan Schwartz, Sunjong Li, Rodrigo Cartaxo, Karthik Ravi, Evan Cantor, Jessica Cummings, Alyssa Paul, Dustin Walling, Matthew Dun, Jason Cain, Jiang Li, Mariella Filbin, Lili Zhao, Chandan Kumar-Sinha, Rajen Mody, Arul Chinnaiyan, Ryo Kurokawa, Drew Pratt, Sriram Venneti, Jacques Grill, Cassie Kline, Sabine Mueller, Adam C Resnick, Javad Nazarian, Sebastian Waszak, Joshua E Allen, Carl Koschmann
Publikováno v:
Neuro-Oncology. 24:vii86-vii87
Patients with H3K27M-mutated diffuse midline glioma (DMG) have no proven effective therapies beyond radiation. ONC201, a DRD2 antagonist and mitochondrial ClpP agonist, has shown promise in this population. Clinical and genetic variables associated w
Autor:
Izac Findlay, Dilana Staudt, Padraic Kearney, Holly McEwen, Ryan Duchatel, Evangeline Jackson, Tyrone Beitaki, Nathan Smith, Nicholas Vitanza, Ron Firestein, Jason Cain, Sabine Mueller, Eddy Pasquier, Carl Koschmann, Esther Hulleman, Javad Nazarian, Mitchell Hansen, Frank Alvaro, Melissa Davis, Sebastian Waszak, Matthew Dun
Publikováno v:
Neuro-Oncology. 24:vii40-vii41
Pediatric high-grade gliomas (pHGG) are the leading cause of cancer-related death in children and young adults. Current treatment strategies are centered on maximal safe resection, followed by radiotherapy, and interrogation of the tumor genome to id
Autor:
Dana Messinger, Micah Harris, Jessica Cummings, Chase Thomas, Tao Yang, Stefan Sweha, Rinette Woo, Robert Siddaway, Martin Burkert, Stefanie Stallard, Tingting Qin, Brendan Mullan, Ruby Siada, Ramya Ravindran, Michael Niculcea, Abigail Dowling, Joshua Bradin, Kevin Ginn, Melissa Gener, Kathleen Dorris, Nicholas Vitanza, Susanne Schmidt, Jasper Spitzer, Jiang Li, Mariella Filbin, Xuhong Cao, Maria Castro, Pedro Lowenstein, Rajen Mody, Arul Chinnaiyan, Pierre-Yves Desprez, Sean McAllister, Matthew Dun, Cynthia Hawkins, Sebastian Waszak, Sriram Venneti, Carl Koschmann, Viveka Yadav
Publikováno v:
Neuro-Oncology. 24:vii40-vii40
Diffuse midline gliomas (DMG) are highly invasive brain tumors with rare survival beyond two years past diagnosis. The mechanism behind tumor invasion is currently not well understood. Previous reports demonstrate upregulation of the protein ID1 with
Autor:
Evangeline Jackson, Ryan Duchatel, Mika Persson, Abdul Mannan, Sridevi Yadavilli, Sarah Parackal, Shaye Game, Wai Chin Chong, Samantha Jayasekara, Marion Le Grand, Padraic Kearney, Alicia Douglas, Izac Findlay, Dilana Staudt, Zacary Germon, David Skerrett-Byrne, Brett Nixon, Nathan Smith, Esther Hulleman, Bryan Day, Geoffrey McCowage, Frank Alvaro, Sebastian Waszak, Martin Larsen, Yolanda Colino-Sanguino, Fatima Valdes-Mora, Andria Rakotomalala, Samuel Meignan, Eddy Pasquier, Nicholas Vitanza, Javad Nazarian, Carl Koschmann, Jason Cain, Sabine Mueller, Matthew Dun
Publikováno v:
Neuro-Oncology. 24:vii211-vii211
Diffuse midline gliomas (DMGs), including those of the pons (diffuse intrinsic pontine glioma - DIPG), are pediatric CNS tumors recognized as the most lethal of all children’s cancers. Palliative radiotherapy remains the only approved treatment, wi
Autor:
Mika Persson, Evangeline Jackson, Ryan Duchatel, Liesl Bramberger, Holly McEwen, Padraic Kearney, Izac Findlay, Alicia Douglas, Birgit Kobbe, Raimund Wagener, Martin Larsen, Pouya Faridi, Jeff Holst, Jemma Mayall, Craig Gedye, Hubert Hondermarck, Jay Horvat, Brett Nixon, Rodrigo Cartaxo, Carl Koschmann, Fatima Valdes-Mora, David Gallego Ortega, Javad Nazarian, Marta M Alonso, Esther Hulleman, Jasper Van der Lugt, Nicholas Vitanza, Sabine Mueller, Matthew Dun
Publikováno v:
Neuro-Oncology. 24:vii272-vii272
Diffuse midline glioma (DMG) is a high-grade glioma with a median overall survival of 9-11 months. Radiotherapy is the only recognized treatment. The DMG tumor microenvironment (TME) contains few, if any, tumor infiltrating lymphocytes (TILs) or infl
Autor:
Yolanda Colino Sanguino, Laura Rodriguez de la Fuente, Dana Kisswani, Padraic Kearney, Evangeline Jackson, Ryan Duchatel, Holly Holliday, Nada Jabado, Maria Tsoli, David Ziegler, Matthew Dun, Fatima Valdes Mora
Publikováno v:
Neuro-Oncology. 24:i26-i27
Diffuse intrinsic pontine glioma (DIPG) is the most aggressive brain tumor found in children with a peak incidence of 5-7 years of age, with median survival after diagnosis less than one year. In more than 60% of DIPG cases, a recurring somatic mutat
Autor:
Javad Nazarian, Matthew Dun, Lindsay Kilburn, Sebastian Waszak, Nicholas Vitanza, Andrea Franson, Mike Prados, Eric Raabe, Ron Firestein, Alexander Beck, Amanda Saratsis, Barak Rotblat, Dannis van Vuurder, Jessica Foster, Esther Hulleman, Cassie Kline, Nalin Gupta, Jason Cain, Carl Koschmann, Sabine Muller
Publikováno v:
Neuro-Oncology. 24:i29-i30
INTRODUCTION: DMG-ACT (DMG- multi-arm Adaptive and Combinatorial Trial) will implement an innovative clinical trial design of combinatorial arms for patients with DMG at all disease stages, that is adaptive to pre-clinical and correlate data generate
Autor:
Carrie Myers, Alyssa Noll, Matthew Biery, Michael Meechan, Sophie Tahiri, Jessica Foster, Matthew Dun, James Olson, Nicholas Vitanza
Publikováno v:
Neuro-Oncology. 24:i32-i32
Diffuse intrinsic pontine glioma (DIPG) is a universally fatal tumor of the pons, most often characterized by mutations in genes encoding histone 3, that led to the classification diffuse midline glioma, H3 K27M-mutant (DMG). However, 15% of DIPG are
Autor:
Carl Koschmann, Abed Rahman Kawakibi, Rohinton Tarapore, Sharon Gardner, Chase Thomas, Rodrigo Cartaxo, Viveka Yadav, Andrew Chi, Sylvia Kurz, Patrick Wen, Isabel Arrillaga, Tracy Batchelor, Nicholas Butowski, Ashley Sumrall, Nicole Shonka, Rebecca Harrison, John De Groot, Minesh Mehta, Yazmin Odia, Matthew Hall, Doured Daghistani, Timothy Cloughesy, Benjamin Ellingson, Michelle Kim, Yoshie Umemura, Hugh Garton, Andrea Franson, Patricia Robertson, Jonathan Schwartz, Bernard Marini, Manjunath Pai, Timothy Phoenix, Sunjong Ji, Evan Cantor, Zachary Miklja, Brendan Mullan, Amy Bruzek, Ruby Siada, Jessica Cummings, Stefanie Stallard, Kyle Wierzbicki, Alyssa Paul, Ian Wolfe, Matthew Dun, Jason Cain, Li Jiang, Mariella Filbin, Pankaj Vats, Chandan Kumar-Sinha, Rajen Mody, Arul Chinnaiyan, Drew Pratt, Sriram Venneti, Guangrong Lu, Sabine Mueller, Adam Resnick, Javad Nazarian, Sebastian Waszak, Joshua Allen
Patients with diffuse midline glioma (DMG) harboring H3 K27M mutation have no proven therapies beyond radiation. ONC201, a DRD2 antagonist and mitochondrial ClpP agonist, has induced early responses in patients with H3 K27M-mutant DMG. We performed a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::06f1acf7b9e4e63c9e411b7056b9a949
https://doi.org/10.21203/rs.3.rs-69706/v1
https://doi.org/10.21203/rs.3.rs-69706/v1
Autor:
Mbah, Nneka E., Myers, Amy L., Sajjakulnukit, Peter, Chung, Chan, Thompson, Joyce K., Hong, Hanna S., Giza, Heather, Dang, Derek, Nwosu, Zeribe C., Shan, Mengrou, Sweha, Stefan R., Maydan, Daniella D., Chen, Brandon, Zhang, Li, Magnuson, Brian, Zhu, Zirui, Radyk, Megan, Lavoie, Brooke, Yadav, Viveka Nand, Koo, Imhoi
Publikováno v:
Nature Communications; 10/17/2024, Vol. 15 Issue 1, p1-21, 21p